GLSI - NASDAQ
Greenwich LifeSciences, Inc.
$24.29
-15%Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
At a Glance
Live SnapshotGreenwich LifeSciences, Inc. Management Team
Mr. Snehal S. Patel
Chief Executive Officer, Chief Financial Officer & Director
Compensation
$918,844
Dr. Frank Joseph Daugherty M.D.
Chief Medical Officer & Director
Mr. Eric Rothe
Founder & Independent Director
Dr. Jaye L. Thompson Ph.D.
Vice President Clinical & Regulatory Affairs
Dr. Christine T. Fischette Ph.D.
Vice President of Business Development
Greenwich LifeSciences, Inc. Insider Positioning
During the last 12 months, insiders have purchased $489K worth of GLSI shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
16.0K
340.17K
0
0.00
+340K
+$340K
6-9 Months
17.5K
149.16K
0
0.00
+149K
+$149K
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Patel Snehal
Director, 10 Percent Owner, Officer: Ceo And Cfo
$489K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $489K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
1 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Unanimous insider buying: Zero selling combined with active buying is rare and typically very bullish. Insiders appear to see significant upside with limited downside risk.
SEC Filings
GLSI - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | November 03, 2025 | November 03, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | November 01, 2024 | November 01, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | October 25, 2023 | October 24, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | October 19, 2022 | October 19, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | October 19, 2021 | October 19, 2021 | 2021 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.